Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.
Cytomegalovirus (CMV) replicates rapidly in its human host with a doubling time of approximately 1 day. Using simple mathematical models we show that the efficacy of the anti-CMV drug ganciclovir (GCV) against wild-type strains is 91.5% [95% confidence interval (CI) 89-94%] when given i.v. (5 mg/kg twice a day) but only 46.5% (95% CI 45-47.5%) when given orally (1 g three times a day) whereas the corresponding figures for a typical GCV-resistant virus are 62% (95% CI 57-66%) and 35% (95% CI 33-37%), respectively. During prolonged periods of GCV therapy we show that the apparent sudden appearance of GCV resistance is explained by the combination of two exponentially increasing populations (wild type and mutant) at doses of GCV that do not completely inhibit CMV replication. Cell culture methods to assess CMV drug resistance in vivo will underestimate its prevalence because of the fitness loss of resistant virus in the absence of therapy. The parameters determined from these models then were used to predict the likely viral load and resistance patterns in patients on prolonged therapy with GCV. The modeled and experimental data showed excellent agreement over extended time periods (up to 270 days of therapy) and provide a framework to predict the virologic course of patients at therapeutic initiation.
Emery
V C
VC
Department of Virology, Royal Free and University College Medical School of University College, Rowland Hill Street, Hampstead, London, NW3 2QG, United Kingdom. v.emery@rfc.ucl.ac.uk
Griffiths
P D
PD
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000284:Administration, Oral; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D015774:Ganciclovir / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D008962:Models, Theoretical; D009154:Mutation; D013997:Time Factors; D019562:Viral Load
D000998:Antiviral Agents; D015774:Ganciclovir